                         SEQUENCE LISTING

<110>  The Regents of the University of California
 
<120>  Methods and Devices for Performing Autoantibody Assays

<130>  034044.172WO1

<150>  US 62/485,616
<151>  2017-04-14

<160>  11    

<170>  PatentIn version 3.5

<210>  1
<211>  180
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NY-ESO-1 peptide based on human sequence

<400>  1

Met Gln Ala Glu Gly Arg Gly Thr Gly Gly Ser Thr Gly Asp Ala Asp 
1               5                   10                  15      


Gly Pro Gly Gly Pro Gly Ile Pro Asp Gly Pro Gly Gly Asn Ala Gly 
            20                  25                  30          


Gly Pro Gly Glu Ala Gly Ala Thr Gly Gly Arg Gly Pro Arg Gly Ala 
        35                  40                  45              


Gly Ala Ala Arg Ala Ser Gly Pro Gly Gly Gly Ala Pro Arg Gly Pro 
    50                  55                  60                  


His Gly Gly Ala Ala Ser Gly Leu Asn Gly Cys Cys Arg Cys Gly Ala 
65                  70                  75                  80  


Arg Gly Pro Glu Ser Arg Leu Leu Glu Phe Tyr Leu Ala Met Pro Phe 
                85                  90                  95      


Ala Thr Pro Met Glu Ala Glu Leu Ala Arg Arg Ser Leu Ala Gln Asp 
            100                 105                 110         


Ala Pro Pro Leu Pro Val Pro Gly Val Leu Leu Lys Glu Phe Thr Val 
        115                 120                 125             


Ser Gly Asn Ile Leu Thr Ile Arg Leu Thr Ala Ala Asp His Arg Gln 
    130                 135                 140                 


Leu Gln Leu Ser Ile Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu Met 
145                 150                 155                 160 


Trp Ile Thr Gln Cys Phe Leu Pro Val Phe Leu Ala Gln Pro Pro Ser 
                165                 170                 175     


Gly Gln Arg Arg 
            180 


<210>  2
<211>  81
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  XAGE-1 peptide based on human sequence

<400>  2

Met Glu Ser Pro Lys Lys Lys Asn Gln Gln Leu Lys Val Gly Ile Leu 
1               5                   10                  15      


His Leu Gly Ser Arg Gln Lys Lys Ile Arg Ile Gln Leu Arg Ser Gln 
            20                  25                  30          


Cys Ala Thr Trp Lys Val Ile Cys Lys Ser Cys Ile Ser Gln Thr Pro 
        35                  40                  45              


Gly Ile Asn Leu Asp Leu Gly Ser Gly Val Lys Val Lys Ile Ile Pro 
    50                  55                  60                  


Lys Glu Glu His Cys Lys Met Pro Glu Ala Gly Glu Glu Gln Pro Gln 
65                  70                  75                  80  


Val 
    


<210>  3
<211>  317
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SOX2 peptide based on human sequence

<400>  3

Met Tyr Asn Met Met Glu Thr Glu Leu Lys Pro Pro Gly Pro Gln Gln 
1               5                   10                  15      


Thr Ser Gly Gly Gly Gly Gly Asn Ser Thr Ala Ala Ala Ala Gly Gly 
            20                  25                  30          


Asn Gln Lys Asn Ser Pro Asp Arg Val Lys Arg Pro Met Asn Ala Phe 
        35                  40                  45              


Met Val Trp Ser Arg Gly Gln Arg Arg Lys Met Ala Gln Glu Asn Pro 
    50                  55                  60                  


Lys Met His Asn Ser Glu Ile Ser Lys Arg Leu Gly Ala Glu Trp Lys 
65                  70                  75                  80  


Leu Leu Ser Glu Thr Glu Lys Arg Pro Phe Ile Asp Glu Ala Lys Arg 
                85                  90                  95      


Leu Arg Ala Leu His Met Lys Glu His Pro Asp Tyr Lys Tyr Arg Pro 
            100                 105                 110         


Arg Arg Lys Thr Lys Thr Leu Met Lys Lys Asp Lys Tyr Thr Leu Pro 
        115                 120                 125             


Gly Gly Leu Leu Ala Pro Gly Gly Asn Ser Met Ala Ser Gly Val Gly 
    130                 135                 140                 


Val Gly Ala Gly Leu Gly Ala Gly Val Asn Gln Arg Met Asp Ser Tyr 
145                 150                 155                 160 


Ala His Met Asn Gly Trp Ser Asn Gly Ser Tyr Ser Met Met Gln Asp 
                165                 170                 175     


Gln Leu Gly Tyr Pro Gln His Pro Gly Leu Asn Ala His Gly Ala Ala 
            180                 185                 190         


Gln Met Gln Pro Met His Arg Tyr Asp Val Ser Ala Leu Gln Tyr Asn 
        195                 200                 205             


Ser Met Thr Ser Ser Gln Thr Tyr Met Asn Gly Ser Pro Thr Tyr Ser 
    210                 215                 220                 


Met Ser Tyr Ser Gln Gln Gly Thr Pro Gly Met Ala Leu Gly Ser Met 
225                 230                 235                 240 


Gly Ser Val Val Lys Ser Glu Ala Ser Ser Ser Pro Pro Val Val Thr 
                245                 250                 255     


Ser Ser Ser His Ser Arg Ala Pro Cys Gln Ala Gly Asp Leu Arg Asp 
            260                 265                 270         


Met Ile Ser Met Tyr Leu Pro Gly Ala Glu Val Pro Glu Pro Ala Ala 
        275                 280                 285             


Pro Ser Arg Leu His Met Ser Gln His Tyr Gln Ser Gly Pro Val Pro 
    290                 295                 300                 


Gly Thr Ala Ile Asn Gly Thr Leu Pro Leu Ser His Met 
305                 310                 315         


<210>  4
<211>  40
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NY-ESO-1: 1-40, residues 1-40 of NY-ESO-1

<400>  4

Met Gln Ala Glu Gly Arg Gly Thr Gly Gly Ser Thr Gly Asp Ala Asp 
1               5                   10                  15      


Gly Pro Gly Gly Pro Gly Ile Pro Asp Gly Pro Gly Gly Asn Ala Gly 
            20                  25                  30          


Gly Pro Gly Glu Ala Gly Ala Thr 
        35                  40  


<210>  5
<211>  41
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NY-ESO-1: 90-130, residues 90-130 of NY-ESO-1

<400>  5

Phe Tyr Leu Ala Met Pro Phe Ala Thr Pro Met Glu Ala Glu Leu Ala 
1               5                   10                  15      


Arg Arg Ser Leu Ala Gln Asp Ala Pro Pro Leu Pro Val Pro Gly Val 
            20                  25                  30          


Leu Leu Lys Glu Phe Thr Val Ser Gly 
        35                  40      


<210>  6
<211>  41
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NY-ESO-1: 120-160, residues 120-160 of NY-ESO-1

<400>  6

Gly Val Leu Leu Lys Glu Phe Thr Val Ser Gly Asn Ile Leu Thr Ile 
1               5                   10                  15      


Arg Leu Thr Ala Ala Asp His Arg Gln Leu Gln Leu Ser Ile Ser Ser 
            20                  25                  30          


Cys Leu Gln Gln Leu Ser Leu Leu Met 
        35                  40      


<210>  7
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NY-ESO-1: 150-180, residues 150-180 of NY-ESO-1

<400>  7

Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu Met Trp Ile Thr Gln Cys 
1               5                   10                  15      


Phe Leu Pro Val Phe Leu Ala Gln Pro Pro Ser Gly Gln Arg Arg 
            20                  25                  30      


<210>  8
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  XAGE-1b: 1-25, residues 1-25 of XAGE-1b

<400>  8

Met Glu Ser Pro Lys Lys Lys Asn Gln Gln Leu Lys Val Gly Ile Leu 
1               5                   10                  15      


His Leu Gly Ser Arg Gln Lys Lys Ile 
            20                  25  


<210>  9
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  XAGE-1b: 57-81, residues 57-81 of XAGE-1b

<400>  9

Gly Val Lys Val Lys Ile Ile Pro Lys Glu Glu His Cys Lys Met Pro 
1               5                   10                  15      


Glu Ala Gly Glu Glu Gln Pro Gln Val 
            20                  25  


<210>  10
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SOX2: 52-87, residues 52-87 of SOX2

<400>  10

Arg Lys Met Ala Gln Glu Asn Pro Lys Met His Asn Ser Glu Ile Ser 
1               5                   10                  15      


Lys Arg Leu Gly Ala Glu Trp Lys Leu Leu Ser Glu Thr Glu Lys 
            20                  25                  30      


<210>  11
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SOX2: 98-124, residues 98-124 of SOX2

<400>  11

Arg Ala Leu His Met Lys Glu His Pro Asp Tyr Lys Tyr Arg Pro Arg 
1               5                   10                  15      


Arg Lys Thr Lys Thr Leu Met Lys Lys Asp Lys 
            20                  25          


